The burgeoning landscape of treatment for obesity and type 2 metabolic disorder is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 https://lorinszn824919.mpeblog.com/69350839/retatrutide-vs-tirzepatide-a-comparative-analysis